Anonymous User
Login / Registration

a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2020; 74(2): 103–110. doi:10.14735/amgh2020103.

Guideline of the Czech Hepatology Society of the ČLS JEP for diagnosis and treatment of non-alcoholic fatty liver disease

Radan Brůha1, Karel Dvořák2, Tomáš Fejfar3, Václav Šmíd1, Pavel Trunečka4

+ Affiliation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users


1. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64(6): 1388–1402. 10.1016/j.jhep.2015.11.004.
2. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67(1): 328–357. doi: 10.1002/hep.29367.
3. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34(3): 274–285. doi: 10.1111/j.1365-2036.2011.04724.x.
4. Zelber-Sagi S, Lotan R, Shlomai A et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol 2012; 56(5): 1145–1151. doi: 10.1016/j.jhep.2011.12.011.
5. Subichin M, Clanton J, Makuszewski M et al. Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery. Surg Obes Relat Dis 2015; 11(1): 137–141. doi: 10.1016/j.soard.2014.06.015.
6. Dvorak K, Hainer R, Petrtyl J et al. The prevalence of nonalcoholic liver steatosis in patients with type 2 diabetes mellitus in the Czech Republic. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015; 159(3): 442–448. doi: 10.5507/bp.2014.033.
7. Younossi ZM, Koenig AB, Abdelatif D et al. Global epidemiology of nonalcoholic fatty liver disease – Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64(1): 73–84. doi: 10.1002/hep.28431.
8. Sung KC, Jeong WS, Wild SH et al. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 2012; 35(4): 717–722. doi: 10.2337/dc11-1853.
9. Wild SH, Morling JR, McAllister DA et al. Type 2 diabetes and risk of hospital admission or death for chronic liver diseases. J Hepatol 2016; 64(6): 1358–1364. doi: 10.1016/j.jhep.2016.01.014.
10. Adams LA, Anstee QM, Tilg H et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66(6): 1138–1153. doi: 10.1136/gutjnl-2017-313884.
11. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129(1): 113–121. doi: 10.1053/j.gastro.2005.04.014.
12. Haflidadottir S, Jonasson JG, Norland H et al. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol 2014; 14: 166. doi: 10.1186/1471-230X-14-166.
13. Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab 2013; 98(9): 3637–3643. doi: 10.1210/jc.2013-1519.
14. Francque SM. The role of non-alcoholic fatty liver disease in cardiovascular disease. Eur Cardiol 2014; 9(1): 10–15. doi: 10.15420/ecr.2014.9.1.10.
15. Athyros VG, Tziomalos K, Gossios TD et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376(9756): 1916–1922. doi: 10.1016/S0140-6736(10)61272-X.
16. Tikkanen MJ, Fayyad R, Faergeman O et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168(4): 3846–3852. doi: 10.1016/j.ijcard.2013.06.024.
17. Lindenmeyer CC, McCullough AJ. The natural history of nonalcoholic fatty liver disease – an evolving view. Clin Liver Dis 2018; 22(1): 11–21. doi: 10.1016/j.cld.2017.08.003.
18. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 2018; 68(2): 268–279. doi: 10.1016/j.jhep.2017.09.003.
19. Abul-Husn NS, Cheng X, Li AH et al. A Protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med 2018; 378(12): 1096–1106. doi: 10.1056/NEJMoa1712191.
20. Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40(12): 1461–1465. doi: 10.1038/ng.257.
21. Krawczyk M, Rau M, Schattenberg JM et al. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. J Lipid Res 2017; 58(1): 247–255. doi: 10.1194/jlr.P067454.
22. Hernaez R. Genetic factors associated with the presence and progression of nonalcoholic fatty liver disease: a narrative review. Gastroenterol Hepatol 2012; 35(1): 32–41. doi: 10.1016/j.gastrohep.2011.08.002.
23. Stender S, Kozlitina J, Nordestgaard BG et al. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet 2017; 49(6): 842–847. doi: 10.1038/ng.3855.
24. Hernaez R, Lazo M, Bonekamp S et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54(3): 1082–1090. doi: 10.1002/hep.24452.
25. Fatty Liver Index (FLI) of Bedogni et al for Predicting Hepatic Steatosis. [online]. Available from:
26. Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology 2014; 147(4): 754–764. doi: 10.1053/j.gastro.2014.07.056.
27. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41(6): 1313–1321. doi: 10.1002/hep.20701.
28. Dvořák K. Možnosti neinvazivní diagnostiky u NAFLD. Gastroent Hepatol 2015; 69(2): 110–115. doi: 10.14735/amgh2015110.
29. NAFLD fibrosis score. Online calculator. [online] Available from:
30. Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45(4): 846–854. doi: 10.1002/hep.21496.
31. Fibrosis-4 (FIB4) Index for Liver Fibrosis. [online]. Available from:
32. Lichtinghagen R, Pietsch D, Bantel H et al. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol 2013; 59(2): 236–242. doi: 10.1016/j.jhep.2013.03.016.
33. Ryan MC, Itsiopoulos C, Thodis T et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 2013; 59(1): 138–143. doi: 10.1016/j.jhep.2013.02.012.
34. Trovato FM, Catalano D, Martines GFet al. Mediterranean diet and non-alcoholic fatty liver disease: the need of extended and comprehensive interventions. Clin Nutr 2015; 34(1): 86–88. doi: 10.1016/j.clnu.2014.01.018.
35. Uribarri J, Woodruff S, Goodman S et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010; 110(6): 911–916. doi: 10.1016/j.jada.2010.03.018.
36. Maersk M, Belza A, Stødkilde-Jørgensen H et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. Am J Clin Nutr 2012; 95(2): 283–289. doi: 10.3945/ajcn.111.022533.
37. Ma J, Fox CS, Jacques PF et al. Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. J Hepatol 2015; 63(2): 462–469. doi: 10.1016/j.jhep.2015.03.032.
38. Santaliestra-Pasías AM, Mouratidou T, Huybrechts I et al. Increased sedentary behaviour is associated with unhealthy dietary patterns in European adolescents participating in the HELENA study. Eur J Clin Nutr 2014; 68(3): 300–308. doi: 10.1038/ejcn.2013.170.
39. Setiawan VW, Wilkens LR, Lu SC et al. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 2015; 148(1): 118–125. doi: 10.1053/j.gastro.2014.10.005.
40. Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008; 47(6): 1947–1954. doi: 10.1002/hep.22292.
41. Fuster D, Samet JH. Alcohol use in patients with chronic liver disease. N Engl J Med 2018; 379(13): 1251–1261. doi: 10.1056/NEJMra1715733.
42. Perseghin G, Lattuada G, De Cobelli F et al. Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care 2007; 30(3): 683–688. doi: 10.2337/dc06-2032
43. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 2008; 48(6): 1791–1798. doi: 10.1002/hep.22525.
44. Hashida R, Kawaguchi T, Bekki M et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol 2017; 66(1): 142–152. doi: 10.1016/j.jhep.2016.08.023.
45. Grøntved A, Hu FB. Television viewing and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a meta-analysis. JAMA 2011; 305(23): 2448–2455. doi: 10.1001/jama.2011.812.
46. Healy GN, Dunstan DW, Salmon J et al. Breaks in sedentary time: beneficial associations with metabolic risk. Diabetes Care 2008; 31(4): 661–666. doi: 10.2337/dc07-2046.
47. Lazo M, Solga SF, Horska A et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010; 33(10): 2156–2163. doi: 10.2337/dc10-0856.
48. Patel NS, Doycheva I, Peterson MR et al. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2015; 13(3): 561–568. doi: 10.1016/j.cgh.2014.08.039.
49. Eckard C, Cole R, Lockwood J et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therap Adv Gastroenterol 2013; 6(4): 249–259. doi: 10.1177/1756283X13484078.
50. Byers T, Sedjo RL. Body fatness as a cause of cancer: epidemiologic clues to biologic mechanisms. Endocr Relat Cancer 2015; 22(3): R125–R134. doi: 10.1530/ERC-14-0580.
51. Musso G, Cassader M, Rosina F et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012; 55(4): 885–904. doi: 10.1007/s00125-011-2446-4.
52. Glass LM, Dickson RC, Anderson JC et al. Total body weight loss of ≥ 10% is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2015; 60(4): 1024–1030. doi: 10.1007/s10620-014-3380-3.
53. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015; 149(2): 367–378. doi: 10.1053/j.gastro.2015.04.005.
54. Lassailly G, Caiazzo R, Buob D et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 2015; 149(2): 379–388. doi: 10.1053/j.gastro.2015.04.014.
55. Mathurin P, Hollebecque A, Arnalsteen L et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137(2): 532–540. doi: 10.1053/j.gastro.2009.04.052.
56. Kintscher U, Bramlage P, Paar WD et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007; 6: 12. doi: 10.1186/1475-2840-6-12.
57. Alam S, Kabir J, Mustafa G et al. Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: a 1-year randomized control trial. Saudi J Gastroenterol 2016; 22(1): 69–76. doi: 10.4103/1319-3767.173762.
58. Goh GB, Pagadala MR, Dasarathy J et al. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int 2015; 35(3): 979–985. doi: 10.1111/liv.12611.
59. Janský P, Rosolová H, Vrablík M. Souhrn Doporučených postupů ESC/EAS
pro diagnostiku a léčbu dyslipidemií z roku 2016. Cor et Vasa 2017; 59: e389–e415.
60. Sato K, Gosho M, Yamamoto T et al. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition 2015; 31(7–9): 923–930. doi: 10.1016/j.nut.2014.11.018.
61. Xu R, Tao A, Zhang S et al. Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis. Int J Clin Exp Med 2015; 8(3): 3924–3934.
62. Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362(18): 1675–1685. doi: 10.1056/NEJMoa0907929.
63. Cusi K, Orsak B, Bril F et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 2016; 165(5): 305–315. doi: 10.7326/M15-1774.
64. Yau H, Rivera K, Lomonaco R et al. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep 2013; 13(3): 329–341. doi: 10.1007/s11892-013-0378-8.
65. Lewis JD, Habel LA, Quesenberry CP et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 2015; 314(3): 265–277. doi: 10.1001/jama.2015.7996.
66. Klein EA, Thompson IM Jr, Tangen CM et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306(14): 1549–1556. doi: 10.1001/jama.2011.1437.
67. Chan JM, Darke AK, Penney KL et al. Selenium- or vitamin E-related gene variants, interaction with supplementation, and risk of high-grade prostate cancer in SELECT. Cancer Epidemiol Biomarkers Prev 2016; 25(7): 1050–1058. doi: 10.1158/1055-9965.EPI-16-0104.
68. Neuschwander-Tetri BA, Loomba R, Sanyal AJ et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385(9972): 956–965. doi: 10.1016/S0140-6736(14)61933-4.
69. Ratziu V, Harrison SA, Francque S et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and - δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 2016; 150(5): 1147–1159. doi: 10.1053/j.gastro.2016.01.038.
70. Connolly JJ, Ooka K, Lim JK. Future pharmacotherapy for non-alcoholic steatohepatitis (NASH): review of phase 2 and 3 trials. J Clin Transl Hepatol 2018; 6(3): 264–275. doi: 10.14218/JCTH.2017.00056.
71. Borena W, Strohmaier S, Lukanova A et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer 2012; 131(1): 193–200. doi: 10.1002/ijc.26338.
72. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126(2): 460–468. doi: 10.1053/j.gastro.2003.10.065.
73. Liu YL, Patman GL, Leathart JB et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014; 61(1): 75–81. doi: 10.1016/j.jhep.2014.02.030.
74. Torres DM, Harrison SA. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis 2012; 32(1): 30–38. doi: 10.1055/s-0032-1306424.
75. Piscaglia F, Svegliati-Baroni G, Barchetti A et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology 2016; 63(3): 827–838. doi: 10.1002/hep.28368.
76. Reig M, Gambato M, Man NK et al. Should patients with NAFLD/NASH be surveyed for HCC? Transplantation 2019; 103(1): 39–44. doi: 10.1097/TP.0000000000002361.
77. Atiq O, Tiro J, Yopp AC et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology 2017; 65(4): 1196–1205. doi: 10.1002/hep.28895.
78. Weinmann A, Alt Y, Koch S et al. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer 2015; 15: 210. doi: 10.1186/s12885-015-1197-x.
79. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 2014; 59(6): 2188–2195. doi: 10.1002/hep.26986.
80. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10(11): 686–690. doi: 10.1038/nrgastro.2013.171.
81. Agopian VG, Kaldas FM, Hong JC et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg 2012; 256(4): 624–633. doi: 10.1097/SLA.0b013e31826b4b7e.
82. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35(1): 105–109. doi: 10.1053/jhep.2002.30318.
83. Spengler EK, O’Leary JG, Te HS et al. Liver transplantation in the obese cirrhotic patient. Transplantation 2017; 101(10): 2288–2296. doi: 10.1097/TP.0000000000001794.
84. Singal AK, Hasanin M, Kaif M et al. Nonalcoholic steatohepatitis is the most rapidly growing indication for simultaneous liver kidney transplantation in the United States. Transplantation 2016; 100(3): 607–612. doi: 10.1097/TP.0000000000000945.
85. Hejlova I, Honsova E, Sticova E et al. Prevalence and risk factors of steatosis after liver transplantation and patient outcomes. Liver Transpl 2016; 22(5): 644–655. doi: 10.1002/lt.24393.
86. Germani G, Laryea M, Rubbia-Brandt L et al. Management of recurrent and de novo NAFLD/NASH after liver transplantation. Transplantation 2019; 103(1): 57–67. doi: 10.1097/TP.0000000000002485.
87. Diwan TS, Rice TC, Heimbach JK et al. Liver transplantation and bariatric surgery: timing and outcomes. Liver Transpl 2018; 24(9): 1280–1287. doi: 10.1002/lt.25303.
88. Pais R, Barritt AS 4th, Calmus Y et al. NAFLD and liver transplantation: current burden and expected challenges. J Hepatol 2016; 65(6): 1245–1257. doi: 10.1016/j.jhep.2016.07.033.
89. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120(16): 1640–1645. doi: 10.1161/CIRCULATIONAHA.109.192644.

Kreditovaný autodidaktický test